1. Appendix Table 2. The association between BMI and clinicopathological factors
BMI (kg/m2) 　
<23, n (%)
23–25, n (%)
≥25, n (%)
p value
177 (40.7)
124 (28.5)
134 (30.8)
sex
male
112 (63.3)
99 (79.8)
107 (79.9)
0.001
female
65 (36.7)
25 (20.2)
27 (20.1)
presentation
incidental
115 (65.0)
94 (75.8)
106 (79.1)
0.013
symptomatic
62 (35.0)
30 (24.2)
28 (20.9)
pT stage 1
118 (66.7)
83 (66.9)
104 (77.6)
0.222 2
21 (11.9)
10 (8.1)
12 (9.0) 3
35 (19.8)
17 (12.7) 4
3 (1.6)
1 (0.8)
1 (0.7)
pN stage
0 or x
171 (96.6)
119 (96.0)
131 (97.8)
0.707
positive
6 (4.4)
5 (4.0)
3 (2.2)
M stage
158 (89.3)
108 (87.1)
125 (93.3)
0.242
19 (10.7)
16 (12.9)
9 (6.7)
nephrectomy type
partial
23 (13.0)
17 (13.7)
21 (15.7)
0.792
total
154 (87.0)
107 (86.3)
113 (84.3)
nuclear grade ≤2
130 (73.5)
92 (74.2)
117 (87.3)
0.007 ≥3
47 (26.5)
32 (25.8)
MVI
negative
134 (75.5)
96 (77.4)
115 (85.8)
0.077
43 (24.3)
28 (22.6)
19 (14.2)
ECOG-PS
159 (89.8)
112 (90.3)
128 (95.5)
0.156 ≥1
18 (10.2)
12 (9.7)
6 (4.5)
CRP
<0.3 mg/dl
125 (70.6)
79 (63.7)
105 (78.4)
0.034
≥0.3 mg/dl
51 (29.4)
45 (36.3)
29 (21.6)
MVI, microscopic venous invasion
ECOG-PS, Eastern Cooperative Oncology Group Performance Status; CRP, C-reactive protein